Regeneron extends $270 million US Ebola treatment deal to 2031

Regeneron has expanded an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply doses of its Ebola treatment, Inmazeb, through 2031. The contract, valued at approximately $270 million, extends a procurement arrangement originally established in 2020.

Inmazeb, which combines three antibodies, was approved by the US Food and Drug Administration in 2020 for treating infections caused by the Zaire ebolavirus. While Inmazeb has shown a reduction in mortality of approximately 55% in clinical trials for low viral load patients, it is not currently an approved treatment for the Bundibugyo variant.

A significant Ebola outbreak, initially identified in May in the Democratic Republic of Congo, has since spread across four countries in Africa, marking the widest geographical spread of the virus ever recorded on the continent. The outbreak has resulted in nearly 10,000 infections and over 4,800 deaths in the DRC alone.

In response to the Bundibugyo variant, Regeneron is testing its experimental therapy, maftivimab, as a potential standalone treatment. Laboratory and animal studies have indicated activity against the Bundibugyo virus, and the company is currently adding maftivimab to the PARTNERS clinical trial.